<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of neuromuscular junction toxins
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of neuromuscular junction toxins
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of neuromuscular junction toxins
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laurie Gutmann, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laura Tormoehlen, MD, FACMT, FAAN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signal transduction at the neuromuscular junction is a complex multistep process required for many of the functions that sustain life. Neuromuscular toxins act in various ways to inhibit this process. These toxins are naturally occurring [
         <a href="#rid1">
          1
         </a>
         ], and some have been developed as biochemical weapons.
        </p>
        <p>
         This topic will briefly discuss the neuromuscular transmission disorders due to botulism, tick paralysis, snake envenomation, latrodectism, organophosphates and carbamates, and hypermagnesemia or hypocalcemia.
        </p>
        <p>
         Acquired myasthenia gravis, congenital and neonatal myasthenia gravis, and Lambert-Eaton myasthenic syndrome are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5153.html" rel="external">
          "Pathogenesis of myasthenia gravis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">
          "Clinical manifestations of myasthenia gravis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">
          "Neuromuscular junction disorders in newborns and infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5174.html" rel="external">
          "Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          THE NEUROMUSCULAR JUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The neuromuscular junction consists of a presynaptic axon terminal and a postsynaptic muscle end plate  (
         <a class="graphic graphic_figure graphicRef62694" href="/z/d/graphic/62694.html" rel="external">
          figure 1
         </a>
         ). Within the presynaptic terminal are vesicles containing acetylcholine, adenosine triphosphate (ATP), magnesium, and calcium [
         <a href="#rid2">
          2,3
         </a>
         ]. Most of these vesicles are bound to the actin cytoskeleton by proteins called synapsins. When an action potential induces opening of calcium channels, increased intracellular calcium levels promote phosphorylation of synapsins. This phosphorylation results in release of the vesicles from their cytoskeletal sites [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         After release from the cytoskeleton, vesicles become bound at the presynaptic membrane terminal in areas called active zones [
         <a href="#rid2">
          2,5
         </a>
         ]. This "docking" allows rapid exocytosis of the vesicles. Docking is mediated by proteins termed "SNARES" (soluble N-ethylmaleimide-sensitive-fusion-attachment protein receptors). SNARES attached to the terminal membrane (t-SNARES) form complexes with proteins located on the vesicle (v-SNARES) [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         Proteins involved in SNARE complexes include vesicle-associated membrane protein (VAMP), which is found on the vesicle surface, along with synaptosomal-associated protein of 25 kD (SNAP-25) and syntaxin, proteins found at the terminal membrane [
         <a href="#rid6">
          6-8
         </a>
         ]. VAMP, syntaxin, and SNAP-25 are targets of the protease activity of botulinum toxin.
        </p>
        <p>
         Phosphorylation of docking proteins occurs in response to increased calcium levels. This induces SNARE complex formation, followed by exocytosis of the vesicle contents [
         <a href="#rid6">
          6,8
         </a>
         ]. The vesicle membrane becomes added to the terminal membrane. Vesicles are recycled when pits form in the terminal membrane and become coated with a protein called clathrin. These clathrin-coated pits then pinch off to form vesicles [
         <a href="#rid9">
          9
         </a>
         ]. Acetylcholine is then synthesized and repackaged into these vesicles.
        </p>
        <p>
         The postsynaptic membrane is heavily folded and invaginated. Acetylcholine receptors are found at the crests of the junctional folds, and voltage-sensitive Na+ channels are concentrated within the folds. The acetylcholine receptors have an ideal binding constant to allow reversible binding of acetylcholine. When bound, ion channels within the receptor are opened with an influx of Na+, and there is a transient depolarization of the end-plate region. If this end-plate potential is large enough, a muscle fiber action potential is generated, which leads to muscle contraction. Acetylcholine remaining in the synapse is rapidly degraded by the enzyme acetylcholinesterase, and the muscle is allowed to repolarize [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          BOTULISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulism is an uncommon and life-threatening disease caused by
         <em>
          Clostridium
         </em>
         bacteria. The botulinum neurotoxin is considered the most potent lethal substance known. In high enough doses, it causes rapid and severe paralysis of skeletal muscles.
        </p>
        <p>
         Botulism is briefly reviewed here and is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Organisms of the
         <em>
          Clostridium
         </em>
         genus are commonly found in soil and include
         <em>
          C. botulinum
         </em>
         ,
         <em>
          C. baratii
         </em>
         , and
         <em>
          C. butyricum
         </em>
         . They are all gram-positive, anaerobic, spore-forming rods, which have evolved to produce a potent neurotoxin.
        </p>
        <p>
         Eight distinct
         <em>
          C. botulinum
         </em>
         toxin types have been described: A, B, C1, C2, D, E, F, and G. Of these eight, types A, B, E, and rarely F and G cause human disease. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Microbiology and pathogenesis'
         </a>
         .)
        </p>
        <p>
         The modern syndrome of botulism occurs in six forms, differentiated by the mode of acquisition:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infant botulism occurs after the ingestion of clostridial spores that then colonize the host's gastrointestinal (GI) tract and release toxin produced in vivo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Food-borne botulism occurs after ingestion of food contaminated by preformed botulinum toxin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wound botulism occurs after infection of a wound by
         <em>
          C. botulinum
         </em>
         with subsequent in vivo production of neurotoxin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iatrogenic botulism can occur with incorrect preparation or administration of botulinum neurotoxin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adult enteric infectious botulism or adult infectious botulism of unknown source is similar to infant botulism in that toxin is produced in vivo in the GI tract of an infected adult host.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhalational botulism is the form that would occur if aerosolized toxin was released in an act of bioterrorism.
        </p>
        <p>
        </p>
        <p>
         Approximately 200 cases of botulism are reported each year in the United States. In 2019, approximately 70 percent of the cases were infant botulism, 20 percent wound botulism, 10 percent food-borne botulism, and the remaining 1 percent were unknown, iatrogenic, or adult intestinal colonization. The incidence of wound botulism has increased due to the use of intravenous drugs [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms range from minor cranial nerve palsies associated with symmetric descending weakness to rapid respiratory arrest. Key features of the botulism syndrome include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of fever
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symmetric neurologic deficits
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preserved responsiveness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal or slow heart rate and normal blood pressure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No sensory deficits with the exception of blurred vision
        </p>
        <p>
        </p>
        <p>
         Fever may be seen with wound botulism, but it probably results from concurrent bacterial infection of the wound by non-clostridial species. Food-borne botulism produces GI symptoms such as nausea, vomiting, or diarrhea. These may precede neurologic symptoms. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Disease presentation and severity are quite variable in infant botulism, most likely as a result of size of the bacterial inoculum and host susceptibility. A detailed discussion of infant botulism is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">
          "Neuromuscular junction disorders in newborns and infants", section on 'Infant botulism'
         </a>
         .)
        </p>
        <p>
         Routine lab tests in botulism are generally nonspecific, and specific laboratory confirmation may take several days. Therefore, the diagnosis is usually clinical. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Neurophysiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrodiagnostic studies (nerve conduction studies and electromyography) are frequently helpful in diagnosis of botulism. Sensory action potentials and nerve conduction velocities are typically normal. However, compound muscle action potential (CMAP) amplitudes are decreased if the presynaptic block is severe enough. Repetitive nerve stimulation (RNS) at frequencies of 2 to 5 Hz depletes readily available stores of acetylcholine from the neuromuscular junction and decreases CMAP amplitudes even further, a finding termed the "decremental response" [
         <a href="#rid12">
          12,13
         </a>
         ]. A decrement of greater than 10 percent is considered abnormal. In more severe cases, the baseline CMAP may be too low to see decremental response.
        </p>
        <p>
         By contrast, increased rates of stimulation (20 to 50 Hz) or exercise cause accumulation of calcium in the presynaptic terminal and increase release of acetylcholine, a finding termed the "incremental response," or "postactivation facilitation"  (
         <a class="graphic graphic_figure graphicRef63756" href="/z/d/graphic/63756.html" rel="external">
          figure 2
         </a>
         ). This can be seen in approximately 60 percent of cases of adult botulism poisoning [
         <a href="#rid13">
          13
         </a>
         ]. The amount of facilitation seen with botulism (40 to 100 percent) is usually less than that seen in Lambert-Eaton myasthenic syndrome (200 percent or more)  (
         <a class="graphic graphic_waveform graphicRef66509" href="/z/d/graphic/66509.html" rel="external">
          waveform 1
         </a>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. No increment or only very mild increment will be seen if the block produced by botulism is too severe. The post-tetanic facilitation may also be extraordinarily prolonged with botulism, occasionally up to four minutes.
        </p>
        <p>
         The electrodiagnostic findings in botulism may change over time. In a small study of 18 patients with food-borne botulism, reduced CMAP amplitudes and postactivation facilitation became less consistent over a period of 4 to 88 days post ingestion [
         <a href="#rid14">
          14
         </a>
         ]. Small voluntary motor unit action potentials were seen in all patients assessed in the acute (4 to 8 days) and early post-acute (32 to 39 days) phases but only 50 percent of patients in the late post-acute phase (66 to 88 days).
        </p>
        <p>
         Postactivation exhaustion, a decrease in CMAP amplitude occurring two to four minutes after maximal muscle contraction, is not present in cases of botulism poisoning [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
         In summary, electromyography diagnosis of botulism should be based on the following findings [
         <a href="#rid12">
          12,13,15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced baseline CMAP amplitude
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postactivation facilitation (between 40 and 200 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of postactivation exhaustion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postactivation facilitation that persists longer than two minutes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Small motor unit action potentials
        </p>
        <p>
        </p>
        <p>
         The sensitivity of RNS is much greater in cases of infantile botulism. (See
         <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">
          "Neuromuscular junction disorders in newborns and infants", section on 'Infant botulism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum antitoxin should be given as soon as botulism is suspected [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          TICK PARALYSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tick paralysis is a toxin-mediated illness characterized by acute onset motor weakness. Several tick species produce a toxin that inhibits transduction at the neuromuscular junction including
         <em>
          Dermacentor
         </em>
         and
         <em>
          Ixodes
         </em>
         species. Neurotoxins impair motor nerve transmission or neuromuscular junction activity. The neurotoxins of
         <em>
          Ixodes
         </em>
         species ticks are known as holocyclotoxins or ixovotoxins [
         <a href="#rid18">
          18
         </a>
         ]. These toxins decrease release of acetylcholine from the presynaptic membrane by inhibiting presynaptic voltage-gated calcium channels [
         <a href="#rid19">
          19
         </a>
         ]. This reduces calcium entry into the nerve terminal, thereby decreasing quanta of acetylcholine released [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Clinical features and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms include progressive anorexia, lethargy, muscle weakness, nystagmus, and an ascending flaccid paralysis. Symptom onset occurs three to seven days after attachment of the tick. The diagnosis of tick paralysis usually relies on the finding of a tick attached to the patient. Tick paralysis is a rare, but easily remedied, cause of ascending paralysis. Therefore, patients with this presentation should always be thoroughly searched for ticks. Unexposed areas such as the scalp, genitalia, and external meatus should be inspected carefully. (See
         <a class="medical medical_review" href="/z/d/html/7900.html" rel="external">
          "Tick paralysis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Electromyography shows a reduced amplitude of compound muscle action potentials (CMAPs) [
         <a href="#rid21">
          21
         </a>
         ]. No abnormalities are seen with repetitive nerve stimulation (RNS) studies [
         <a href="#rid21">
          21,22
         </a>
         ]. There may be subtle abnormalities of motor nerve conduction velocity and sensory action potentials.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Removal of the tick is the primary treatment of tick paralysis. The tick can be removed with forceps placed as close to the skin as possible. Both the tick and the skin should be inspected carefully to ensure complete removal of the tick's mouth parts.
        </p>
        <p>
         Clinical improvement is generally fairly rapid after removal of American ticks. Symptoms may continue and worsen for two to three days after removal of Australian ticks. For severely affected patients, an antivenom derived from dogs is available. (See
         <a class="medical medical_review" href="/z/d/html/7900.html" rel="external">
          "Tick paralysis", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SNAKE ENVENOMATION
         </span>
        </p>
        <p class="headingAnchor" id="H282157603">
         <span class="h2">
          Types of snakes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Five families/subfamilies of snakes produce venom that is toxic to humans, three of which cause clinically significant neuromuscular transmission disorders [
         <a href="#rid23">
          23,24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elapidae (cobras, mambas, coral snakes, sea kraits)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hydrophidae (sea snakes)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crotalinae (rattlesnakes)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4050324883">
         <span class="h2">
          Venom toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Snake toxins produced affect either the presynaptic or postsynaptic junction.
        </p>
        <p>
         Toxins affecting the presynaptic junction include beta-bungarotoxin (krait), notexin (tiger snake), taipoxin (Taipan), and crotoxin (Brazilian rattlesnake). These toxins have phospholipase A2 activity and are called SPANS (snake presynaptic phospholipase A2 neurotoxins). They catalyze the hydrolysis of phosphatidylcholine, a major component of the plasma membrane, forming lysophosphatides and releasing both saturated and unsaturated fatty acids [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         The exact mechanism of toxicity is undefined, but hydrolysis of these phospholipids leads to massive release of synaptic vesicles. Fusion of synaptic vesicles with the presynaptic membrane is induced, followed by inhibited reformation of the vesicles after exocytosis. Further neurotransmitter release is therefore prevented [
         <a href="#rid28">
          28,29
         </a>
         ]. Poisoned nerve terminals show an absence of vesicles [
         <a href="#rid30">
          30
         </a>
         ], which causes delayed degeneration of the motor nerve terminals. Recovery requires nerve terminal regeneration, a process that may take weeks. The presynaptic neurotoxins also possess myotoxic activity, which may lead to degeneration of skeletal muscle and death from acute renal failure.
        </p>
        <p>
         The postsynaptic-acting toxins are present in venom of snakes from the Elapidae family [
         <a href="#rid27">
          27,31
         </a>
         ]. They bind irreversibly to the acetylcholine receptor site and prevent the opening of the associated sodium channel [
         <a href="#rid31">
          31
         </a>
         ]. As an example, alpha-bungarotoxin from the krait produces a postjunctional neuromuscular blockade.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Clinical features and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local and systemic symptoms from envenomation vary by species of snake and may be used to help discriminate between species in circumstances when the snake was not identified. (See
         <a class="medical medical_review" href="/z/d/html/6594.html" rel="external">
          "Snakebites worldwide: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         In many cases, snake venom neurotoxins affect the cranial nerves first, resulting in ptosis, ophthalmoplegia, dysarthria, dysphagia, and drooling. This progresses to weakness of limb muscles [
         <a href="#rid32">
          32,33
         </a>
         ]. Clotting time may also be increased [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         The postsynaptic toxins produce findings on electrodiagnostic studies identical to those seen in myasthenia gravis, since the mechanism of disease is similar [
         <a href="#rid34">
          34
         </a>
         ]. Repetitive nerve stimulation (RNS) produces a decremental response. (See
         <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">
          "Diagnosis of myasthenia gravis", section on 'Electrodiagnostic confirmation for seronegative and atypical presentations'
         </a>
         .)
        </p>
        <p>
         Envenomation by the timber rattlesnake causes myokymia  (
         <a class="graphic graphic_waveform graphicRef69008" href="/z/d/graphic/69008.html" rel="external">
          waveform 2
         </a>
         ). Spontaneous bursts of motor unit potentials manifest as doublets and multiplets on electromyography [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Extensive diagnostic workup is generally unnecessary, since most patients are fully aware of the snake bite.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of snake bites is briefly reviewed here and discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/93182.html" rel="external">
          "Snakebites worldwide: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121865.html" rel="external">
          "Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6599.html" rel="external">
          "Evaluation and management of coral snakebites"
         </a>
         .)
        </p>
        <p>
         Frequently, the species of snake producing the bite is unknown  (
         <a class="graphic graphic_figure graphicRef73865" href="/z/d/graphic/73865.html" rel="external">
          figure 3
         </a>
         ), and it is unclear if the bite was actually venomous. However, with any potentially venomous bite or sting, the patient should be observed for several hours before it is decided that the event is benign.
        </p>
        <p>
         Antivenom is available and effective for postsynaptic neurotoxins. It accelerates dissociation of the toxin from the postsynaptic receptor. Presynaptic toxins have no response to antivenom [
         <a href="#rid32">
          32
         </a>
         ]. Cutting, biting, sucking, or excising tissue at the site is contraindicated, as these measures do not help remove venom and may introduce infection.
        </p>
        <p class="headingAnchor" id="H937716317">
         <span class="h1">
          LATRODECTISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Latrodectus
         </em>
         species of spiders, including black widow spiders (
         <em>
          Latrodectus mactans
         </em>
         ), have a multicomponent venom that contains alpha-latrotoxin. Latrotoxin binds to a presynaptic neurexin receptor and calcium-independent receptor for alpha-latrotoxin. This binding stimulates neurotransmitter release, including acetylcholine, resulting in vesicle depletion.
        </p>
        <p class="headingAnchor" id="H2567140380">
         <span class="h2">
          Clinical features and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial symptom with latrodectism is a sharp, local pain at the bite site. The local reaction is generally mild but can include local erythema with central clearing and swelling of proximal lymph nodes. Neuromuscular symptoms begin with autonomic dysfunction evolving from tachycardia and hypotension to bradycardia and hypertension. Nausea, diaphoresis, diffuse muscle spasms, and rigidity including abdominal musculature follow. Spasms start at the bite site then spread proximally.
        </p>
        <p>
         Diagnosis is clinical, as laboratory abnormalities are nonspecific (eg, leukocytosis and elevated creatinine kinase). There is no available laboratory assay specific to latrodectism [
         <a href="#rid36">
          36-38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88938.html" rel="external">
          "Widow spider bites: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2067369561">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management begins with supporting respiratory and circulatory status. Symptomatic management with opioids for pain and benzodiazepines for spasms is the mainstay of treatment. Antivenom (if available) is generally reserved for severe or life-threatening cases that are inadequately treated with the supportive and symptomatic care above. Local wound care and tetanus prophylaxis should be given as indicated [
         <a href="#rid37">
          37-42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6510.html" rel="external">
          "Widow spider bites: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          DRUGS
         </span>
        </p>
        <p class="headingAnchor" id="H2397999522">
         <span class="h2">
          Common agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the neuromuscular blocking agents used during anesthesia, several other drugs [
         <a href="#rid43">
          43,44
         </a>
         ] can affect transmission at the neuromuscular junction, including the following [
         <a href="#rid45">
          45
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuromuscular blocking anesthetic agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune checkpoint inhibitors (ICI)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycoside antibiotics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluoroquinolone antibiotics [
         <a href="#rid46">
          46
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrolide antibiotics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta blockers
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          Magnesium sulfate
         </a>
         (see
         <a class="local">
          'Hypermagnesemia/hypocalcemia'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Botulinum toxin
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
         , used to treat Wilson disease and rheumatoid arthritis, can induce production of antibodies to acetylcholine receptors. This results in a clinical presentation of myasthenia gravis (MG) with the antibodies affecting post-synaptic transmission. (See
         <a class="medical medical_review" href="/z/d/html/5168.html" rel="external">
          "Differential diagnosis of myasthenia gravis", section on 'Other conditions'
         </a>
         .)
        </p>
        <p>
         Therapy with ICI, immunomodulatory antibodies to treat several forms of cancer, can cause neuromuscular disorders such as MG and other neurologic complications such as Guillain-Barré syndrome, aseptic meningitis, encephalitis, or transverse myelitis [
         <a href="#rid47">
          47-52
         </a>
         ]. ICI therapy may produce acetylcholine receptor (AChR) antibodies and cause exacerbation of underlying MG or new-onset clinical presentation of MG [
         <a href="#rid47">
          47,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Neurologic'
         </a>
         .)
        </p>
        <p>
         The other drugs listed above are generally safe but may cause reduced transmission at the neuromuscular junction in cases of overdose or when used in patients who have underlying disease of the neuromuscular junction, such as myasthenia gravis  (
         <a class="graphic graphic_table graphicRef100362" href="/z/d/graphic/100362.html" rel="external">
          table 1
         </a>
         ) or Lambert-Eaton myasthenic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/5157.html" rel="external">
          "Overview of the treatment of myasthenia gravis", section on 'Avoidance of drugs that may exacerbate myasthenia'
         </a>
         .)
        </p>
        <p>
         Aminoglycoside antibiotics inhibit both pre- and postsynaptic transmission [
         <a href="#rid54">
          54,55
         </a>
         ].
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          Phenytoin
         </a>
         causes both pre- and postsynaptic effects and prevents the depolarization required for neurotransmission. There is controversy over the nature of the action of beta blockers on the neuromuscular junction. They may produce a depolarizing or nondepolarizing blockade or have a local anesthetic action [
         <a href="#rid56">
          56,57
         </a>
         ].
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         , with chronic use, may compete with calcium in the presynaptic region and reduce the release of acetylcholine from nerve terminals [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Clinical features and management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Generally, the offending drug is simply withdrawn, and the diagnosis is made by the resultant clinical improvement. The diagnosis may also be aided by administration of cholinesterase inhibitors.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In aminoglycoside poisoning, low rates of repetitive nerve stimulation (RNS) produce a decremental response, with post-tetanic facilitation [
         <a href="#rid54">
          54
         </a>
         ]. The facilitation exceeds that seen in myasthenia gravis [
         <a href="#rid54">
          54
         </a>
         ]. The decremental response is also larger than occurs in myasthenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
         produces a myasthenia syndrome, the findings on electrodiagnostic studies are the same as those in patients with myasthenia  (
         <a class="graphic graphic_waveform graphicRef75502" href="/z/d/graphic/75502.html" rel="external">
          waveform 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5130.html" rel="external">
          "Diagnosis of myasthenia gravis", section on 'Electrodiagnostic confirmation for seronegative and atypical presentations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The clinical features are usually mild and affect primarily the extraocular muscles. The diagnosis can also be aided by finding elevated serum acetylcholine receptor antibodies. Clinical improvement is usually complete within one year of drug discontinuation. (See
         <a class="medical medical_review" href="/z/d/html/5168.html" rel="external">
          "Differential diagnosis of myasthenia gravis", section on 'Other conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In ICI-induced neuropathies or MG, onset of symptoms may begin within four weeks after ICI therapy initiation. There is a higher incidence of severe bulbar and respiratory compromise in the presentation of MG, requiring early recognition and treatment to potentially avoid intubation. Treatment depends on symptom severity but typically includes withdrawal of ICI therapy, supportive care, and immunosuppressive treatment with glucocorticoids or other therapies  (
         <a class="graphic graphic_table graphicRef116846" href="/z/d/graphic/116846.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Checkpoint inhibitor-associated neuropathies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          ORGANOPHOSPHATE AND CARBAMATE TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Organophosphates and carbamates are potent inhibitors of acetylcholinesterase, causing excess acetylcholine concentrations in the synapse. These compounds are formed as the esters of phosphoric or phosphorothioic acid or as the esters of carbamic acid and are commonly used as pesticides. Each year, over 3000 cases of organophosphate or carbamate poisoning occur in the United States, and 3,000,000 people are exposed worldwide [
         <a href="#rid59">
          59
         </a>
         ]. Exposure routes include oral ingestion, inhalation, or dermal contact. Organophosphorus "nerve gases" (eg, tabun [GA], sarin [GB], soman [GD]) have also been developed.
        </p>
        <p>
         Organophosphate and carbamate toxicity is briefly reviewed here; a detailed discussion is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Pathophysiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the organophosphates and the carbamates have a common mode of action (anticholinesterase activity leading to an overabundance of acetylcholine in the synapse), there are significant differences between their reactions with the enzyme. The bond between an organophosphorus ester and the active site of the acetylcholinesterase enzyme is extremely stable, and these compounds are referred to as irreversible inhibitors. The carbamates interact with acetylcholinesterase in a fashion similar to acetylcholine. They bind noncovalently and the free, active enzyme is released.
        </p>
        <p>
         The spontaneous hydrolysis of organophosphates from acetylcholinesterase is generally very slow. Oximes, specifically
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         , are typically used to induce more rapid dephosphorylation. If the oxime is not administered soon enough after acetylcholinesterase has been inhibited, an alkoxy group may be lost from the phosphorylated enzyme, resulting in a conformational change, known as "aging." Aging can occur within minutes for some compounds or may take up to days. Once aging has occurred, oximes can no longer induce dephosphorylation.
        </p>
        <p>
         The excess synaptic acetylcholine produced by organophosphates and carbamates binds muscarinic receptors in the central nervous system (CNS) and the parasympathetic portion of the autonomic nervous system. It also binds nicotinic receptors in the CNS, sympathetic and parasympathetic ganglia, and neuromuscular junction. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Mechanism of action'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since both sympathetic and parasympathetic systems are involved, symptoms of organophosphate and carbamate poisoning include typical muscarinic signs (lacrimation, bradycardia, bronchospasm) and nicotinic signs (mydriasis, tachycardia, weakness, hypertension). These result from the accumulation of acetylcholine in sympathetic ganglia and at the adrenal medulla  (
         <a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">
          table 3
         </a>
         ). Increased depolarization at nicotinic neuromuscular synapses results in muscle weakness and flaccid paralysis.
        </p>
        <p>
         The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         CNS symptoms may also be present including anxiety, confusion, seizures, and coma.
        </p>
        <p>
         Ten to 40 percent of patients develop a distinct neurologic disorder 24 to 96 hours after organophosphorus agent poisoning, referred to as the "intermediate syndrome." Characteristic neurologic findings include cranial nerve abnormalities, neck flexion and proximal muscle weakness, respiratory insufficiency, and decreased deep tendon reflexes.
        </p>
        <p>
         A delayed symmetrical motor axonal polyneuropathy, termed "organophosphorus agent-induced delayed neuropathy" (OPIDN), may occur one to three weeks after exposure to specific organophosphorus agents, including chlorpyrifos.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Neurophysiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrodiagnostic studies in organophosphate poisoning demonstrate repetitive compound muscle action potentials (CMAPs) in response to a single stimulus to the nerve [
         <a href="#rid61">
          61
         </a>
         ]. This is caused by excess accumulation of acetylcholine in the synapse and subsequent depolarization of the postsynaptic muscle membrane. The presynaptic receptors are also activated. This combined effect results in repetitive discharges in response to a single stimulus. Repetitive nerve stimulation (RNS) results in decrement of the CMAP [
         <a href="#rid61">
          61
         </a>
         ]. In early stages of organophosphate poisoning, a decrement-increment response may be seen with higher rates of stimulation. This response may recur later, as clinical improvement is seen [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds; the clinical features of cholinergic excess should indicate the possibility of organophosphate poisoning. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emergency management of organophosphate or carbamate poisoning often requires endotracheal intubation and volume resuscitation  (
         <a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">
          table 3
         </a>
         ). All cases require aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Management'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         is used for symptomatic relief of muscarinic symptoms. It does not reverse the paralysis caused by neuromuscular blockade that results from nicotinic receptor stimulation. Atropine dosing should be titrated to the therapeutic end point of the clearing of respiratory secretions and the cessation of bronchoconstriction. Specific dosing regimens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Atropine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          Pralidoxime
         </a>
         and other oximes are effective in treating both muscarinic and nicotinic symptoms. Pralidoxime should
         <strong>
          not
         </strong>
         be administered without concurrent
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , which prevents worsening symptoms due to transient oxime-induced acetylcholinesterase inhibition. Oxime therapy is reserved for patients with evidence of severe cholinergic toxicity inadequately treated with atropine, neuromuscular dysfunction, or exposure to organophosphorus agents known to cause delayed neurotoxicity. Dosing regimens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Pralidoxime'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          HYPERMAGNESEMIA/HYPOCALCEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A surplus of magnesium or a deficiency of calcium may cause inhibition of acetylcholine release. Magnesium has a calcium channel blocking effect that decreases entry of calcium into cells. It also decreases the amount of acetylcholine released and depresses the excitability of the muscle membrane [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Hypocalcemia results in an uncoupling of synaptic release of neurotransmitters (glutamate, acetylcholine, gamma-aminobutyric acid [GABA]) in response to an action potential at the nerve terminal. This is because the proteins involved in synaptic vesicle docking and fusion interact in a calcium-dependent manner [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/833.html" rel="external">
          "Clinical manifestations of hypocalcemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2166664259">
         <span class="h2">
          Clinical features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypermagnesemia produces proximal muscle weakness, which may progress to respiratory insufficiency. Ocular muscles are generally spared. The administration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         to mothers with eclampsia has resulted in hypermagnesemia in infants with the development of weakness and respiratory depression. (See
         <a class="medical medical_review" href="/z/d/html/831.html" rel="external">
          "Hypermagnesemia: Causes, symptoms, and treatment", section on 'Neuromuscular effects'
         </a>
         .)
        </p>
        <p>
         Hypermagnesemia is an uncommon problem in the absence of magnesium administration or renal failure. Concentrated sources of magnesium include antacids, enemas, and total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/831.html" rel="external">
          "Hypermagnesemia: Causes, symptoms, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of hypermagnesemia or hypocalcemia is generally made by demonstrating elevated serum magnesium levels or decreased calcium levels and observing clinical improvement as levels normalize.
        </p>
        <p>
         Electrodiagnostic studies show low-amplitude compound muscle action potentials (CMAPs), decremental response to low-frequency stimulation, and post-tetanic facilitation.
        </p>
        <p class="headingAnchor" id="H442037900">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anatomy
         </strong>
         – The neuromuscular junction consists of a presynaptic axon terminal and a postsynaptic muscle end plate  (
         <a class="graphic graphic_figure graphicRef62694" href="/z/d/graphic/62694.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'The neuromuscular junction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Botulism
         </strong>
         – Botulism is an uncommon and life-threatening disease caused by
         <em>
          Clostridium
         </em>
         bacteria. The botulinum neurotoxin is considered the most potent lethal substance known. Symptoms range from minor cranial nerve palsies associated with symmetric descending weakness to rapid respiratory arrest. In high doses, it causes rapid and severe paralysis of skeletal muscles. Botulinum antitoxin should be given as soon as botulism is suspected. (See
         <a class="local">
          'Botulism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5509.html" rel="external">
          "Botulism", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tick paralysis
         </strong>
         – Several tick species produce a toxin that inhibits transduction at the neuromuscular junction by blocking influx of sodium ions. Symptoms include anorexia, lethargy, muscle weakness, nystagmus, and an ascending flaccid paralysis. Removal of the tick is the primary treatment. (See
         <a class="local">
          'Tick paralysis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7900.html" rel="external">
          "Tick paralysis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Snake envenomation
         </strong>
         – Three families of snakes produce venom causing neuromuscular transmission disorders. Snake venom neurotoxins affect the cranial nerves first, resulting in ptosis, ophthalmoplegia, dysarthria, dysphagia, and drooling. Symptoms progress to weakness of limb muscles. Antivenom is available and effective for postsynaptic neurotoxins. (See
         <a class="local">
          'Snake envenomation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/93182.html" rel="external">
          "Snakebites worldwide: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121865.html" rel="external">
          "Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6599.html" rel="external">
          "Evaluation and management of coral snakebites"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Latrodectism
         </strong>
         – Latrodectism from a black widow spider bite causes diffuse muscle spasms and rigidity with hypertension, nausea, diaphoresis. Treatment includes benzodiazepines for muscle spasms, opioids for pain management, and respiratory support. Antivenom (equine derived) is reserved for severe cases but does carry risk of anaphylaxis and serum sickness. (See
         <a class="local">
          'Latrodectism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drugs
         </strong>
         – In addition to the neuromuscular blocking agents used during anesthesia, a number of other drugs can affect transmission at the neuromuscular junction, including neuromuscular blocking anesthetic agents,
         <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">
          D-penicillamine
         </a>
         , immune checkpoint inhibitors (ICI), aminoglycoside, fluoroquinolone, and macrolide antibiotics, beta blockers, glucocorticoids,
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         , and botulinum toxin. Typically, the offending drug is withdrawn, and the diagnosis is made by the resultant clinical improvement. Management of symptoms due to ICI may also include administration of glucocorticoids. (See
         <a class="local">
          'Drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Organophosphates and carbamates
         </strong>
         – Organophosphates and carbamates are potent inhibitors of acetylcholinesterase and are commonly used as pesticides. Symptoms of organophosphate and carbamate poisoning include typical muscarinic signs (lacrimation, bradycardia, bronchospasm) and nicotinic signs (mydriasis, tachycardia, weakness, hypertension). The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds. Emergency management includes respiratory support.
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         is used for muscarinic symptoms;
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         is added for severe symptoms, including weakness  (
         <a class="graphic graphic_table graphicRef63540" href="/z/d/graphic/63540.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Organophosphate and carbamate toxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrolyte abnormalities
         </strong>
         – A surplus of magnesium or a deficiency of calcium may cause inhibition of acetylcholine release. The administration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         may cause weakness and respiratory depression. Hypermagnesemia is an uncommon problem in the absence of magnesium administration or renal failure. (See
         <a class="local">
          'Hypermagnesemia/hypocalcemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1919437442">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Tracy Weimer, MD (deceased), who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Senanayake N, Román GC. Disorders of neuromuscular transmission due to natural environmental toxins. J Neurol Sci 1992; 107:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker VP. The structure and function of cholinergic synaptic vesicles. The Third Thudichum Lecture. Biochem Soc Trans 1984; 12:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner JA, Carlson SS, Kelly RB. Chemical and physical characterization of cholinergic synaptic vesicles. Biochemistry 1978; 17:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benfenati F, Valtorta F, Rubenstein JL, et al. Synaptic vesicle-associated Ca2+/calmodulin-dependent protein kinase II is a binding protein for synapsin I. Nature 1992; 359:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyer F, Peper K, Akert K, et al. Ultrastructure of the "active zone" in the frog neuromuscular junction. Brain Res 1973; 62:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheng ZH, Westenbroek RE, Catterall WA. Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. J Bioenerg Biomembr 1998; 30:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Söllner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993; 362:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80:717.
          </a>
         </li>
         <li class="breakAll">
          Schwartz JH. Chemical messengers: small molecules and peptides. In: Principles of Neural Science, 3rd ed, Kandel ER, Schwartz JH, Jessell TM (Eds), Appleton and Lange, 1991. p.229.
         </li>
         <li class="breakAll">
          Dwyer T. The electrochemical basis of nerve function. In: Fundamental Neuroscience for Basic and Clinical Applications, 3rd ed, Haines D (Ed), Elsevier, Singapore 2006. p.41.
         </li>
         <li class="breakAll">
          CDC. National Botulism Surveillance Summary, 2019 https://www.cdc.gov/botulism/surv/2019/index.html (Accessed on September 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005; 84:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982; 5:S28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boccagni C, Prestandrea C, D'Agostino T, et al. Neurophysiological patterns of acute and post-acute foodborne botulism. Muscle Nerve 2021; 64:435.
          </a>
         </li>
         <li class="breakAll">
          Trontelj JV, Sanders DB, Stalber EV. Electrophysiologic methods for assessing neuromuscular transmission. In: Neuromuscular Function and Disease, Brown WF, Bolton CF, Aminoff MJ (Eds), WB Saunders Company, 2002. p.431.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep 2021; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalk CH, Benstead TJ, Pound JD, Keezer MR. Medical treatment for botulism. Cochrane Database Syst Rev 2019; 4:CD008123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felz MW, Smith CD, Swift TR. A six-year-old girl with tick paralysis. N Engl J Med 2000; 342:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper BJ, Spence I. Temperature-dependent inhibition of evoked acetylcholine release in tick paralysis. Nature 1976; 263:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chand KK, Lee KM, Lavidis NA, et al. Tick holocyclotoxins trigger host paralysis by presynaptic inhibition. Sci Rep 2016; 6:29446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherington M, Synder RD. Tick paralysis. Neurophysiologic studies. N Engl J Med 1968; 278:95.
          </a>
         </li>
         <li class="breakAll">
          Kimura J. Myasthenia gravis and other disorders of neuromuscular transmission. In: Electrodiagnosis on Diseases of Nerve and Muscle: Principles and Practice, Kimura J (Ed), Oxford University Press, 2001. p.765.
         </li>
         <li class="breakAll">
          Mebs D. Venomous and Poisonous Animals: A Handbook for Biologists, Toxicologists and Toxinologists, Physicians and Pharmacists, Medpharm Scientific Publishers CRC Press, Boca Raton 2002. p.239.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warrell DA. Snake bite. Lancet 2010; 375:77.
          </a>
         </li>
         <li class="breakAll">
          Kini RM. Venom Phospholipase A2 Enzymes: Structure, Function, and Mechanism, Wiley, Chichester 1997.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis RL, Gutmann L. Snake venoms and the neuromuscular junction. Semin Neurol 2004; 24:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karalliedde L. Animal toxins. Br J Anaesth 1995; 74:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon RW, Harris JB. Nerve terminal damage by beta-bungarotoxin: its clinical significance. Am J Pathol 1999; 154:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly S, Trevett AJ, Nwokolo NC, et al. Neuromuscular effects of Papuan Taipan snake venom. Ann Neurol 1995; 38:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JB, Grubb BD, Maltin CA, Dixon R. The neurotoxicity of the venom phospholipases A(2), notexin and taipoxin. Exp Neurol 2000; 161:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgson WC, Wickramaratna JC. In vitro neuromuscular activity of snake venoms. Clin Exp Pharmacol Physiol 2002; 29:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JB, Goonetilleke A. Animal poisons and the nervous system: what the neurologist needs to know. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 3:iii40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White J, Warrell D, Eddleston M, et al. Clinical toxinology--where are we now? J Toxicol Clin Toxicol 2003; 41:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Usgaonkar RS. Myasthenia gravis--like picture resulting from snake bite. J Indian Med Assoc 1968; 50:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brick JF, Gutmann L. Rattlesnake venom-induced myokymia. Muscle Nerve 1982; 5:S98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss HS, Binder LS. A retrospective review of black widow spider envenomation. Ann Emerg Med 1987; 16:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark RF, Wethern-Kestner S, Vance MV, Gerkin R. Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases. Ann Emerg Med 1992; 21:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monte AA, Bucher-Bartelson B, Heard KJ. A US perspective of symptomatic Latrodectus spp. envenomation and treatment: a National Poison Data System review. Ann Pharmacother 2011; 45:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curran-Sills G, Wilson SM, Bennett R. A Review of Black Widow (Araneae: Theridiidae) Envenomation, Epidemiology, and Antivenom Utilization in Canada. J Med Entomol 2021; 58:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Offerman SR, Daubert GP, Clark RF. The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series. Perm J 2011; 15:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyte CO, Cushing TA, Heard KJ. Anaphylaxis to black widow spider antivenom. Am J Emerg Med 2012; 30:836.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dart RC, Bush SP, Heard K, et al. The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Ann Emerg Med 2019; 74:439.
          </a>
         </li>
         <li class="breakAll">
          Myasthenia Gravis Foundation of America. CAUTIONARY DRUGS FOR MG PATIENTS https://myasthenia.org/Newly-Diagnosed/Cautionary-Drugs-for-MG-Patients (Accessed on September 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard JF Jr. Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieb JP. Fluoroquinolone antibiotics block neuromuscular transmission. Neurology 1998; 50:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019; 7:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011; 22:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93:e1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013; 13:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitt JR, Kreple C, Mahmood N, et al. Autoimmune pancerebellitis associated with pembrolizumab therapy. Neurology 2018; 91:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sechi E, Markovic SN, McKeon A, et al. Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes. Neurology 2020; 95:e2442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argov Z, Mastaglia FL. Drug therapy: Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 301:409.
          </a>
         </li>
         <li class="breakAll">
          Argov Z, Wirguin I. Drugs and the neuromuscular junction pharmacotherapy of transmission disorders and drug-induced myasthenic syndromes. In: Handbook of Myasthenia Gravis and Myasthenic Syndromes, Lisak RP (Ed), Marcel Dekker, New York 1994. p.295.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wislicki L. Excitatory and depressant effects of beta-adrenoceptor blocking agents on skeletal muscle. Arch Int Pharmacodyn Ther 1969; 182:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werman R, Wislicki L. Propranolol, a curariform and cholinomimetic agent at the frog neuromuscular junction. Comp Gen Pharmacol 1971; 2:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vizi ES, Illés P, Rónai A, Knoll J. Effect of lithium on acetylcholine release and synthesis. Neuropharmacology 1972; 11:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med 2001; 27:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besser R, Gutmann L, Dillmann U, et al. End-plate dysfunction in acute organophosphate intoxication. Neurology 1989; 39:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med 1987; 316:761.
          </a>
         </li>
         <li class="breakAll">
          Shnider SM, Levinson G. Anesthesia for obstetrics. In: Anesthesia, 4th ed, Churchill Livingstone, New York 1994. p.2031.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5139 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1315843" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Disorders of neuromuscular transmission due to natural environmental toxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6237945" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The structure and function of cholinergic synaptic vesicles. The Third Thudichum Lecture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/656382" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Chemical and physical characterization of cholinergic synaptic vesicles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328883" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Synaptic vesicle-associated Ca2+/calmodulin-dependent protein kinase II is a binding protein for synapsin I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4760515" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Ultrastructure of the "active zone" in the frog neuromuscular junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9758330" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8455717" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : SNAP receptors implicated in vesicle targeting and fusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10747206" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Neurotoxins affecting neuroexocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10747206" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Neurotoxins affecting neuroexocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10747206" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Neurotoxins affecting neuroexocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10747206" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Neurotoxins affecting neuroexocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16034233" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Advances in the diagnosis of neuromuscular junction disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6763148" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Electrophysiologic methods as an aid in diagnosis of botulism: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34255868" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neurophysiological patterns of acute and post-acute foodborne botulism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34255868" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Neurophysiological patterns of acute and post-acute foodborne botulism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33956777" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30993666" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Medical treatment for botulism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10631277" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A six-year-old girl with tick paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/185525" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Temperature-dependent inhibition of evoked acetylcholine release in tick paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27389875" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Tick holocyclotoxins trigger host paralysis by presynaptic inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5634485" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tick paralysis. Neurophysiologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5634485" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tick paralysis. Neurophysiologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5634485" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Tick paralysis. Neurophysiologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20109866" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Snake bite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20109866" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Snake bite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15257514" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Snake venoms and the neuromuscular junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7718380" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Animal toxins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027403" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nerve terminal damage by beta-bungarotoxin: its clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8526464" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Neuromuscular effects of Papuan Taipan snake venom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10686073" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The neurotoxicity of the venom phospholipases A(2), notexin and taipoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12165047" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : In vitro neuromuscular activity of snake venoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316044" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Animal poisons and the nervous system: what the neurologist needs to know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12807310" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Clinical toxinology--where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5666165" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Myasthenia gravis--like picture resulting from snake bite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7170003" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rattlesnake venom-induced myokymia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3800095" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A retrospective review of black widow spider envenomation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1351707" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22116992" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A US perspective of symptomatic Latrodectus spp. envenomation and treatment: a National Poison Data System review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33432350" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A Review of Black Widow (Araneae: Theridiidae) Envenomation, Epidemiology, and Antivenom Utilization in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22058673" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The treatment of black widow spider envenomation with antivenin latrodectus mactans: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21641165" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anaphylaxis to black widow spider antivenom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30926190" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30926190" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The Efficacy of Antivenin Latrodectus (Black Widow) Equine Immune F(ab')2 Versus Placebo in the Treatment of Latrodectism: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27358333" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : International consensus guidance for management of myasthenia gravis: Executive summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2161128" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Adverse drug effects on neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9521283" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fluoroquinolone antibiotics block neuromuscular transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31753014" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21357649" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Anti-CTLA-4 antibody-induced Guillain-Barrésyndrome in a melanoma patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31405908" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23487828" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Neurological immune-related adverse events of ipilimumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29875219" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Autoimmune pancerebellitis associated with pembrolizumab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24482447" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32796130" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/223053" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Drug therapy: Disorders of neuromuscular transmission caused by drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/223053" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Drug therapy: Disorders of neuromuscular transmission caused by drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4391894" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Excitatory and depressant effects of beta-adrenoceptor blocking agents on skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4269641" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Propranolol, a curariform and cholinomimetic agent at the frog neuromuscular junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5047942" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effect of lithium on acetylcholine release and synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11398695" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical features of patients with acute organophosphate poisoning requiring intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2927681" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : End-plate dysfunction in acute organophosphate intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3029588" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
